Obalon Therapeutics Inc (OBLN) SEC Filing 8-K Material Event for the period ending Thursday, October 3, 2019

Obalon Therapeutics Inc

CIK: 1427570 Ticker: OBLN

View differences made from one to another to evaluate Obalon Therapeutics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Obalon Therapeutics Inc.


Assess how Obalon Therapeutics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Obalon Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


Ticker: OBLN
CIK: 1427570
Form Type: 8-K Corporate News
Accession Number: 0001427570-19-000112
Submitted to the SEC: Thu Oct 03 2019 9:15:33 AM EST
Accepted by the SEC: Thu Oct 03 2019
Period: Thursday, October 3, 2019
Industry: Surgical And Medical Instruments And Apparatus
  1. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: